CoChat

The road toward AAV-mediated gene therapy of Duchenne muscular dystrophy

Bengtsson, Niclas E., Tasfaout, Hichem, Chamberlain, Jeffrey S. · 2025 · Molecular Therapy
Cited by 40

The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.ymthe.2025.03.065

Cites

46 of 46 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 46 references

Research works printed but not linked: 154

  1. Monaco, 1985, Detection of deletions spanning the Duchenne muscular dystrophy locus using a tightly linked DNA segment, Nature, 316, 842, 10.1038/316842a0 · DOI · Paper page
  2. Monaco, 1986, Isolation of candidate cDNA clones for portions of the Duchenne muscular dystrophy gene, Nature, 323, 646, 10.1038/323646a0 · DOI · Paper page
  3. Burghes, 1987, A cDNA clone from the Duchenne/Becker muscular dystrophy gene, Nature, 328, 434, 10.1038/328434a0 · DOI · Paper page
  4. Koenig, 1988, The complete sequence of dystrophin predicts a rod-shaped cytoskeletal protein, Cell, 53, 219, 10.1016/0092-8674(88)90383-2 · DOI · Paper page
  5. Flanigan, 2009, Mutational spectrum of DMD mutations in dystrophinopathy patients: application of modern diagnostic techniques to a large cohort, Hum. Mutat., 30, 1657, 10.1002/humu.21114 · DOI · Paper page
  6. Monaco, 1988, An explanation for the phenotypic differences between patients bearing partial deletions of the DMD locus, Genomics, 2, 90, 10.1016/0888-7543(88)90113-9 · DOI · Paper page
  7. Malhotra, 1988, Frame-shift deletions in patients with Duchenne and Becker muscular dystrophy, Science, 242, 755, 10.1126/science.3055295 · DOI · Paper page
  8. Koenig, 1989, The molecular basis for Duchenne versus Becker muscular dystrophy: correlation of severity with type of deletion, Am. J. Hum. Genet., 45, 498
  9. Baumbach, 1989, Molecular and clinical correlations of deletions leading to Duchenne and Becker muscular dystrophies, Neurology, 39, 465, 10.1212/WNL.39.4.465 · DOI · Paper page
  10. Beggs, 1991, Exploring the molecular basis for variability among patients with Becker muscular dystrophy: dystrophin gene and protein studies, Am. J. Hum. Genet., 49, 54
  11. Love, 1991, Becker muscular dystrophy patient with a large intragenic dystrophin deletion: Implications for functional minigenes and gene therapy, J. Med. Genet., 28, 860, 10.1136/jmg.28.12.860 · DOI
  12. Passos-Bueno, 1994, Half the dystrophin gene is apparently enough for a mild clinical course: confirmation of its potential use for gene therapy, Hum. Mol. Genet., 3, 919, 10.1093/hmg/3.6.919 · DOI
  13. Davies, 2024, Long-term clinical follow-up of a family with Becker muscular dystrophy associated with a large deletion in the DMD gene, Neuromuscul. Disord., 39, 5, 10.1016/j.nmd.2024.04.004 · DOI
  14. Kunkel, 1986, Analysis of deletions in DNA from patients with Becker and Duchenne muscular dystrophy, Nature, 322, 73, 10.1038/322073a0 · DOI · Paper page
  15. Chamberlain, 1988, Deletion screening of the Duchenne muscular dystrophy locus via multiplex DNA amplification, Nucleic Acids Res., 16, 11141, 10.1093/nar/16.23.11141 · DOI · Paper page
  16. Beggs, 1990, Detection of 98% of DMD/BMD gene deletions by polymerase chain reaction, Hum. Genet., 86, 45, 10.1007/BF00205170 · DOI · Paper page
  17. Chamberlain, 1992, Diagnosis of Duchenne and Becker muscular dystrophies by polymerase chain reaction: A multicenter study, JAMA, 267, 2609, 10.1001/jama.1992.03480190051030 · DOI
  18. Chapman, 1989, Recovery of induced mutations for X chromosome-linked muscular dystrophy in mice, Proc. Natl. Acad. Sci. USA, 86, 1292, 10.1073/pnas.86.4.1292 · DOI · Paper page
  19. Cox, 1993, New mdx mutation disrupts expression of muscle and nonmuscle isoforms of dystrophin, Nat. Genet., 4, 87, 10.1038/ng0593-87 · DOI · Paper page
  20. Im, 1996, Differential expression of dystrophin isoforms in strains of mdx mice with different mutations, Hum. Mol. Genet., 5, 1149, 10.1093/hmg/5.8.1149 · DOI · Paper page
  21. Zubrzycka-Gaarn, 1988, The Duchenne muscular dystrophy gene product is localized in sarcolemma of human skeletal muscle, Nature, 333, 466, 10.1038/333466a0 · DOI · Paper page
  22. Hoffman, 1987, Dystrophin: the protein product of the Duchenne muscular dystrophy locus, Cell, 51, 919, 10.1016/0092-8674(87)90579-4 · DOI · Paper page
  23. Hoffman, 1988, Characterization of dystrophin in muscle-biopsy specimens from patients with Duchenne's or Becker's muscular dystrophy, N. Engl. J. Med., 318, 1363, 10.1056/NEJM198805263182104 · DOI · Paper page
  24. Ervasti, 1991, Membrane organization of the dystrophin-glycoprotein complex, Cell, 66, 1121, 10.1016/0092-8674(91)90035-W · DOI · Paper page
  25. Ibraghimov-Beskrovnaya, 1992, Primary structure of dystrophin-associated glycoproteins linking dystrophin to the extracellular matrix, Nature, 355, 696, 10.1038/355696a0 · DOI · Paper page
  26. Wan, 2025, Structure and assembly of the dystrophin glycoprotein complex, Nature, 637, 1252, 10.1038/s41586-024-08310-2 · DOI
  27. Liu, 2025, Native DGC structure rationalizes muscular dystrophy-causing mutations, Nature, 637, 1261, 10.1038/s41586-024-08324-w · DOI
  28. Brenman, 1995, Nitric oxide synthase complexed with dystrophin and absent from skeletal muscle sarcolemma in Duchenne muscular dystrophy, Cell, 82, 743, 10.1016/0092-8674(95)90471-9 · DOI · Paper page
  29. Montanaro, 1999, alpha-Dystroglycan is a laminin receptor involved in extracellular matrix assembly on myotubes and muscle cell viability, J. Cell Biol., 145, 1325, 10.1083/jcb.145.6.1325 · DOI
  30. Ramaswamy, 2011, Lateral transmission of force is impaired in skeletal muscles of dystrophic mice and very old rats, J. Physiol., 589, 1195, 10.1113/jphysiol.2010.201921 · DOI · Paper page
  31. Lee, 1991, Expression of recombinant dystrophin and its localization to the cell membrane, Nature, 349, 334, 10.1038/349334a0 · DOI
  32. Jaynes, 1988, The muscle creatine kinase gene is regulated by multiple upstream elements, including a muscle-specific enhancer, Mol. Cell. Biol., 8, 62
  33. Cox, 1993, Overexpression of dystrophin in transgenic mdx mice eliminates dystrophic symptoms without toxicity [see comments], Nature, 364, 725, 10.1038/364725a0 · DOI · Paper page
  34. Scott, 2002, Viral vectors for gene transfer of micro-mini-or full-length dystrophin, Neuromuscul. Disord., 12, S23, 10.1016/S0960-8966(02)00078-0 · DOI
  35. Wolff, 1990, Direct gene transfer into mouse muscle in vivo, Science, 247, 1465, 10.1126/science.1690918 · DOI · Paper page
  36. Fritz, 1995, Expression of deletion-containing dystrophins in mdx muscle: implications for gene therapy and dystrophin function, Pediatr. Res., 37, 693, 10.1203/00006450-199506000-00004 · doi:10.1203/00006450-199506000-00004
  37. Acsadi, 1991, Human dystrophin expression in mdx mice after intramuscular injection of DNA constructs, Nature, 352, 815, 10.1038/352815a0 · DOI · Paper page
  38. Romero, 2004, Phase I Study of Dystrophin Plasmid-Based Gene Therapy in Duchenne/Becker Muscular Dystrophy, Hum. Gene Ther., 15, 1065, 10.1089/hum.2004.15.1065 · DOI
  39. Stratford-Perricaudet, 1992, Widespread long-term gene transfer to mouse skeletal muscles and heart, J. Clin. Invest., 90, 626, 10.1172/JCI115902 · DOI · Paper page
  40. Ragot, 1993, Efficient adenovirus-mediated transfer of a human minidystrophin gene to skeletal muscle of mdx mice, Nature, 361, 647, 10.1038/361647a0 · DOI · Paper page
  41. Acsadi, 1994, A differential efficiency of adenovirus-mediated in vivo gene transfer into skeletal muscle cells of different maturity, Hum. Mol. Genet., 3, 579, 10.1093/hmg/3.4.579 · DOI · Paper page
  42. Zoltick, 2001, Biology of E1-deleted adenovirus vectors in nonhuman primate muscle, J. Virol., 75, 5222, 10.1128/JVI.75.11.5222-5229.2001 · DOI
  43. Carmen, 2001, A death in the laboratory: the politics of the Gelsinger aftermath, Mol. Ther., 3, 425, 10.1006/mthe.2001.0305 · DOI
  44. Mitani, 1995, Rescue, propagation, and partial purification of a helper virus-dependent adenovirus vector, Proc. Natl. Acad. Sci. USA, 92, 3854, 10.1073/pnas.92.9.3854 · DOI · Paper page
  45. Kumar-Singh, 1996, Encapsidated adenovirus minichromosomes allow delivery and expression of a 14 kb dystrophin cDNA to muscle cells, Hum. Mol. Genet., 5, 913, 10.1093/hmg/5.7.913 · DOI · Paper page
  46. Greelish, 1999, Stable restoration of the sarcoglycan complex in dystrophic muscle perfused with histamine and a recombinant adeno-associated viral vector, Nat. Med., 5, 439, 10.1038/7439 · DOI · Paper page
  47. DelloRusso, 2002, Functional correction of adult mdx mouse muscle using gutted adenoviral vectors expressing full-length dystrophin, Proc. Natl. Acad. Sci. USA, 99, 12979, 10.1073/pnas.202300099 · DOI · Paper page
  48. Dunckley, 1993, Direct retroviral-mediated transfer of a dystrophin minigene into mdx mouse muscle in vivo, Hum. Mol. Genet., 2, 717, 10.1093/hmg/2.6.717 · DOI
  49. Roberts, 2002, Stable micro-dystrophin gene transfer using an integrating adeno-retroviral hybrid vector ameliorates the dystrophic pathology in mdx mouse muscle, Hum. Mol. Genet., 11, 1719, 10.1093/hmg/11.15.1719 · DOI
  50. Kobinger, 2003, Correction of the dystrophic phenotype by in vivo targeting of muscle progenitor cells, Hum. Gene Ther., 14, 1441, 10.1089/104303403769211655 · DOI
  51. Kimura, 2010, Dystrophin delivery to muscles of mdx mice using lentiviral vectors leads to myogenic progenitor targeting and stable gene expression, Mol. Ther., 18, 206, 10.1038/mt.2009.253 · DOI · Paper page
  52. Hindi, 2023, Enveloped viruses pseudotyped with mammalian myogenic cell fusogens target skeletal muscle for gene delivery, Cell, 186, 2062, 10.1016/j.cell.2023.03.033 · DOI
  53. Kessler, 1996, Gene delivery to skeletal muscle results in sustained expression and systemic delivery of a therapeutic protein, Proc. Natl. Acad. Sci. USA, 93, 14082, 10.1073/pnas.93.24.14082 · DOI · Paper page
  54. Xiao, 1996, Efficient long-term gene transfer into muscle tissue of immunocompetent mice by adeno-associated virus vector, J. Virol., 70, 8098, 10.1128/jvi.70.11.8098-8108.1996 · DOI · Paper page
  55. Muzyczka, 1992, Use of adeno-associated virus as a general transduction vector for mammalian cells, Curr. Top. Microbiol. Immunol., 158, 97
  56. Corrado, 1996, Transgenic mdx mice expressing dystrophin with a deletion in the actin-binding domain display a “mild Becker” phenotype, J. Cell Biol., 134, 873, 10.1083/jcb.134.4.873 · DOI · Paper page
  57. Warner, 2002, Expression of Dp260 in muscle tethers the actin cytoskeleton to the dystrophin-glycoprotein complex and partially prevents dystrophy, Hum. Mol. Genet., 11, 1095, 10.1093/hmg/11.9.1095 · DOI
  58. Phelps, 1995, Expression of full-length and truncated dystrophin mini-genes in transgenic mdx mice, Hum. Mol. Genet., 4, 1251, 10.1093/hmg/4.8.1251 · DOI · Paper page
  59. Wells, 1995, Expression of human full-length and minidystrophin in transgenic mdx mice: implications for gene therapy of Duchenne muscular dystrophy, Hum. Mol. Genet., 4, 1245, 10.1093/hmg/4.8.1245 · DOI · Paper page
  60. Harper, 2002, Modular flexibility of dystrophin: Implications for gene therapy of Duchenne muscular dystrophy, Nat. Med., 8, 253, 10.1038/nm0302-253 · DOI · Paper page
  61. Harper, 2002, Spectrin-like repeats from dystrophin and alpha-actinin-2 are not functionally interchangeable, Hum. Mol. Genet., 11, 1807, 10.1093/hmg/11.16.1807 · DOI
  62. Rafael, 1994, Prevention of dystrophic pathology in mdx mice by a truncated dystrophin isoform, Hum. Mol. Genet., 3, 1725, 10.1093/hmg/3.10.1725 · DOI
  63. Crawford, 2000, Assembly of the dystrophin-associated protein complex does not require the dystrophin COOH-terminal domain, J. Cell Biol., 150, 1399, 10.1083/jcb.150.6.1399 · DOI · Paper page
  64. Rafael, 1996, Forced expression of dystrophin deletion constructs reveals structure-function correlations, J. Cell Biol., 134, 93, 10.1083/jcb.134.1.93 · DOI · Paper page
  65. Jaynes, 1986, Transcriptional regulation of the muscle creatine kinase gene and regulated expression in transfected mouse myoblasts, Mol. Cell. Biol., 6, 2855
  66. Wang, 2000, Adeno-associated virus vector carrying human minidystrophin genes effectively ameliorates muscular dystrophy in mdx mouse model, Proc. Natl. Acad. Sci. USA, 97, 13714, 10.1073/pnas.240335297 · DOI · Paper page
  67. Sakamoto, 2002, Micro-dystrophin cDNA ameliorates dystrophic phenotypes when introduced into mdx mice as a transgene, Biochem. Biophys. Res. Commun., 293, 1265, 10.1016/S0006-291X(02)00362-5 · DOI
  68. Bostick, 2008, Adeno-Associated Virus Serotype-9 Microdystrophin Gene Therapy Ameliorates Electrocardiographic Abnormalities in mdx Mice, Hum. Gene Ther., 19, 851, 10.1089/hum.2008.058 · DOI · Paper page
  69. Lai, 2009, Dystrophins carrying spectrin-like repeats 16 and 17 anchor nNOS to the sarcolemma and enhance exercise performance in a mouse model of muscular dystrophy, J. Clin. Invest., 119, 624, 10.1172/JCI36612 · DOI · Paper page
  70. Banks, 2007, Functional capacity of dystrophins carrying deletions in the N-terminal actin-binding domain, Hum. Mol. Genet., 16, 2105, 10.1093/hmg/ddm158 · DOI · Paper page
  71. Banks, 2010, The polyproline site in hinge 2 influences the functional capacity of truncated dystrophins, PLoS Genet., 6, 10.1371/journal.pgen.1000958 · DOI · Paper page
  72. Ramos, 2019, Development of novel micro-dystrophins with enhanced functionality, Mol. Ther., 27, 623, 10.1016/j.ymthe.2019.01.002 · DOI · Paper page
  73. Hauser, 2000, Analysis of muscle creatine kinase regulatory elements in recombinant adenoviral vectors, Mol. Ther., 2, 16, 10.1006/mthe.2000.0089 · DOI · Paper page
  74. Gregorevic, 2006, rAAV6-microdystrophin preserves muscle function and extends lifespan in severely dystrophic mice, Nat. Med., 12, 787, 10.1038/nm1439 · DOI · Paper page
  75. Hartigan-O'Connor, 2001, Immune evasion by muscle-specific gene expression in dystrophic muscle, Mol. Ther., 4, 525, 10.1006/mthe.2001.0496 · DOI · Paper page
  76. Stedman, 2000, Phase I clinical trial utilizing gene therapy for limb girdle muscular dystrophy: alpha-beta-gamma-or delta-sarcoglycan gene delivered with intramuscular instillations of adeno-associated vectors, Hum. Gene Ther., 11, 777, 10.1089/10430340050015671 · DOI
  77. Mendell, 2009, Limb-girdle muscular dystrophy type 2D gene therapy restores alpha-sarcoglycan and associated proteins, Ann. Neurol., 66, 290, 10.1002/ana.21732 · DOI · Paper page
  78. Mendell, 2024, Practical Considerations for Delandistrogene Moxeparvovec Gene Therapy in Patients With Duchenne Muscular Dystrophy, Pediatr. Neurol., 153, 11, 10.1016/j.pediatrneurol.2024.01.003 · DOI
  79. Morris, 2022, IGNITE DMD Study of SGT-001 Microdystrophin Gene Therapy for Duchenne Muscular Dystrophy: Long-Term Outcomes and Biomarker Update, Mol. Ther., 30, 553
  80. Crudele, 2019, AAV-based gene therapies for the muscular dystrophies, Hum. Mol. Genet., 28, R102, 10.1093/hmg/ddz128 · DOI · Paper page
  81. Koo, 2011, Delivery of AAV2/9-microdystrophin genes incorporating helix 1 of the coiled-coil motif in the C-terminal domain of dystrophin improves muscle pathology and restores the level of alpha1-syntrophin and alpha-dystrobrevin in skeletal muscles of mdx mice, Hum. Gene Ther., 22, 1379, 10.1089/hum.2011.020 · DOI · Paper page
  82. Li, 1999, Synthetic muscle promoters: activities exceeding naturally occurring regulatory sequences, Nat. Biotechnol., 17, 241, 10.1038/6981 · DOI · Paper page
  83. Towbin, 1993, X-linked dilated cardiomyopathy: Molecular genetic evidence of linkage to the Duchenne muscular dystrophy (dystrophin) gene at the Xp21 locus, Circulation, 87, 1854, 10.1161/01.CIR.87.6.1854 · DOI · Paper page
  84. Townsend, 2009, Cardiac consequences to skeletal muscle-centric therapeutics for Duchenne muscular dystrophy, Trends Cardiovasc. Med., 19, 50, 10.1016/j.tcm.2009.04.006 · DOI
  85. Townsend, 2008, Emergent dilated cardiomyopathy caused by targeted repair of dystrophic skeletal muscle, Mol. Ther., 16, 832, 10.1038/mt.2008.52 · DOI · Paper page
  86. Servais, 2023, 261st ENMC International Workshop: Management of safety issues arising following AAV gene therapy. 17th-19th June 2022, Hoofddorp, The Netherlands, Neuromuscul. Disord., 33, 884, 10.1016/j.nmd.2023.09.008 · DOI
  87. Bonnemann, 2023, Dystrophin Immunity after Gene Therapy for Duchenne's Muscular Dystrophy, N. Engl. J. Med., 388, 2294, 10.1056/NEJMc2212912 · DOI
  88. Yue, 2008, A single intravenous injection of adeno-associated virus serotype-9 leads to whole body skeletal muscle transduction in dogs, Mol. Ther., 16, 1944, 10.1038/mt.2008.207 · DOI · Paper page
  89. Le Guiner, 2023, Evaluation of an AAV9-mini-dystrophin gene therapy candidate in a rat model of Duchenne muscular dystrophy, Mol. Ther. Methods Clin. Dev., 30, 30, 10.1016/j.omtm.2023.05.017 · DOI
  90. Birch, 2023, Assessment of systemic AAV-microdystrophin gene therapy in the GRMD model of Duchenne muscular dystrophy, Sci. Transl. Med., 15, 10.1126/scitranslmed.abo1815 · DOI
  91. Tasfaout, 2024, Split intein-mediated protein trans-splicing to express large dystrophins, Nature, 632, 192, 10.1038/s41586-024-07710-8 · DOI · Paper page
  92. Tabebordbar, 2021, Directed evolution of a family of AAV capsid variants enabling potent muscle-directed gene delivery across species, Cell, 184, 4919, 10.1016/j.cell.2021.08.028 · DOI · Paper page
  93. Odom, 2008, Microutrophin delivery through rAAV6 increases lifespan and improves muscle function in dystrophic dystrophin/utrophin-deficient mice, Mol. Ther., 16, 1539, 10.1038/mt.2008.149 · DOI · Paper page
  94. Kennedy, 2018, Micro-utrophin Improves Cardiac and Skeletal Muscle Function of Severely Affected D2/mdx Mice, Mol. Ther. Methods Clin. Dev., 11, 92, 10.1016/j.omtm.2018.10.005 · DOI
  95. Song, 2019, Non-immunogenic utrophin gene therapy for the treatment of muscular dystrophy animal models, Nat. Med., 25, 1505, 10.1038/s41591-019-0594-0 · DOI · Paper page
  96. Odom, 2022, Deimmunized micro-dystrophin vectors blunt patient immunity in vitro & restore cardiac functional deficits in vivo in mdx4cv DMD mice, Mol. Ther., 30, 20
  97. Liu, 2022, Obtaining protein foldability information from computational models of AlphaFold2 and RoseTTAFold, Comput. Struct. Biotechnol. J., 20, 4481, 10.1016/j.csbj.2022.08.034 · DOI
  98. Schoeder, 2021, Modeling Immunity with Rosetta: Methods for Antibody and Antigen Design, Biochemistry, 60, 825, 10.1021/acs.biochem.0c00912 · DOI
  99. Rohl, 2004, Protein structure prediction using Rosetta, Methods Enzymol., 383, 66, 10.1016/S0076-6879(04)83004-0 · DOI · Paper page
  100. Wasala, 2018, Cardiac-Specific Expression of DeltaH2-R15 Mini-Dystrophin Normalized All Electrocardiogram Abnormalities and the End-Diastolic Volume in a 23-Month-Old Mouse Model of Duchenne Dilated Cardiomyopathy, Hum. Gene Ther., 29, 737, 10.1089/hum.2017.144 · DOI
  101. El Andari, 2022, Semirational bioengineering of AAV vectors with increased potency and specificity for systemic gene therapy of muscle disorders, Sci. Adv., 8, 10.1126/sciadv.abn4704 · DOI
  102. Vu Hong, 2024, An engineered AAV targeting integrin alpha V beta 6 presents improved myotropism across species, Nat. Commun., 15, 7965, 10.1038/s41467-024-52002-4 · DOI
  103. Kodippili, 2018, Dual AAV Gene Therapy for Duchenne Muscular Dystrophy with a 7-kb Mini-Dystrophin Gene in the Canine Model, Hum. Gene Ther., 29, 299, 10.1089/hum.2017.095 · DOI · Paper page
  104. Albini, 2023, Assessment of Therapeutic Potential of a Dual AAV Approach for Duchenne Muscular Dystrophy, Int. J. Mol. Sci., 24, 10.3390/ijms241411421 · DOI
  105. Lindley, 2024, Ribozyme-activated mRNA trans-ligation enables large gene delivery to treat muscular dystrophies, Science, 386, 762, 10.1126/science.adp8179 · DOI
  106. Li, 2008, Protein trans-splicing as a means for viral vector-mediated in vivo gene therapy, Hum. Gene Ther., 19, 958, 10.1089/hum.2008.009 · DOI · Paper page
  107. Tasfaout, 2025, Expression of full-length dystrophin reverses muscular dystrophy defects in young and old mdx4cv mice., manuscript in revision
  108. Zhou, 2024, Systemic delivery of full-length dystrophin in Duchenne muscular dystrophy mice, Nat. Commun., 15
  109. Palmieri, 2024, In Silico Structural Prediction for the Generation of Novel Performant Midi-Dystrophins Based on Intein-Mediated Dual AAV Approach, Int. J. Mol. Sci., 25, 10.3390/ijms251910444 · DOI
  110. Herzog, 1997, Stable gene transfer and expression of human blood coagulation factor IX after intramuscular injection of recombinant adeno-associated virus, Proc. Natl. Acad. Sci. USA, 94, 5804, 10.1073/pnas.94.11.5804 · DOI · Paper page
  111. Kaplitt, 1994, Long-term gene expression and phenotypic correction using adeno-associated virus vectors in the mammalian brain, Nat. Genet., 8, 148, 10.1038/ng1094-148 · DOI · Paper page
  112. Yang, 1999, Concatamerization of adeno-associated virus circular genomes occurs through intermolecular recombination, J. Virol., 73, 9468, 10.1128/JVI.73.11.9468-9477.1999 · DOI · Paper page
  113. Nakai, 2000, Increasing the size of rAAV-mediated expression cassettes in vivo by intermolecular joining of two complementary vectors, Nat. Biotechnol., 18, 527, 10.1038/75390 · DOI · Paper page
  114. Li, 2015, Precise correction of the dystrophin gene in duchenne muscular dystrophy patient induced pluripotent stem cells by TALEN and CRISPR-Cas9, Stem Cel. Rep., 4, 143, 10.1016/j.stemcr.2014.10.013 · DOI · Paper page
  115. Long, 2016, Postnatal genome editing partially restores dystrophin expression in a mouse model of muscular dystrophy, Science, 351, 400, 10.1126/science.aad5725 · DOI · Paper page
  116. Nelson, 2016, In vivo genome editing improves muscle function in a mouse model of Duchenne muscular dystrophy, Science, 351, 403, 10.1126/science.aad5143 · DOI · Paper page
  117. Bengtsson, 2016, Progress and prospects of gene therapy clinical trials for the muscular dystrophies, Hum. Mol. Genet., 25, R9, 10.1093/hmg/ddv420 · DOI · Paper page
  118. Xu, 2016, CRISPR-mediated Genome Editing Restores Dystrophin Expression and Function in mdx Mice, Mol. Ther., 24, 564, 10.1038/mt.2015.192 · DOI · Paper page
  119. Moretti, 2020, Somatic gene editing ameliorates skeletal and cardiac muscle failure in pig and human models of Duchenne muscular dystrophy, Nat. Med., 26, 207, 10.1038/s41591-019-0738-2 · DOI · Paper page
  120. Bengtsson, 2022, Comparison of dystrophin expression following gene editing and gene replacement in an aged preclinical DMD animal model, Mol. Ther., 30, 2176, 10.1016/j.ymthe.2022.02.003 · DOI
  121. Nelson, 2019, Long-term evaluation of AAV-CRISPR genome editing for Duchenne muscular dystrophy, Nat. Med., 25, 427, 10.1038/s41591-019-0344-3 · DOI · Paper page
  122. Bengtsson, 2021, Dystrophin gene-editing stability is dependent on dystrophin levels in skeletal but not cardiac muscles, Mol. Ther., 29, 1070, 10.1016/j.ymthe.2020.11.003 · DOI
  123. Mauro, 1961, Satellite cell of skeletal muscle fibers, J. Biophys. Biochem. Cytol., 9, 493, 10.1083/jcb.9.2.493 · DOI · Paper page
  124. Goldstein, 2019, In situ modification of tissue stem and progenitor cell genomes, Cell Rep., 27, 1254, 10.1016/j.celrep.2019.03.105 · DOI
  125. Kwon, 2020, In vivo gene editing of muscle stem cells with adeno-associated viral vectors in a mouse model of Duchenne muscular dystrophy, Mol. Ther. Methods Clin. Dev., 19, 320, 10.1016/j.omtm.2020.09.016 · DOI
  126. Nance, 2019, AAV9 edits muscle stem cells in normal and dystrophic adult mice, Mol. Ther., 27, 1568, 10.1016/j.ymthe.2019.06.012 · DOI
  127. Young, 2016, A single crispr-cas9 deletion strategy that targets the majority of DMD patients restores dystrophin function in hIPSC-derived muscle cells, Cell Stem Cell, 18, 533, 10.1016/j.stem.2016.01.021 · DOI · Paper page
  128. Goyenvalle, 2004, Rescue of dystrophic muscle through U7 snRNA-mediated exon skipping, Science, 306, 1796, 10.1126/science.1104297 · DOI · Paper page
  129. Vulin, 2012, Muscle function recovery in golden retriever muscular dystrophy after AAV1-U7 exon skipping, Mol. Ther., 20, 2120, 10.1038/mt.2012.181 · DOI
  130. Aupy, 2020, Long-Term Efficacy of AAV9-U7snRNA-Mediated Exon 51 Skipping in mdx52 Mice, Mol. Ther. Methods Clin. Dev., 17, 1037, 10.1016/j.omtm.2020.04.025 · DOI · Paper page
  131. Wein, 2022, Systemic delivery of an AAV9 exon-skipping vector significantly improves or prevents features of Duchenne muscular dystrophy in the Dup2 mouse, Mol. Ther. Methods Clin. Dev., 26, 279, 10.1016/j.omtm.2022.07.005 · DOI
  132. Gushchina, 2023, Persistence of exon 2 skipping and dystrophin expression at 18 months after U7snRNA-mediated therapy in the Dup2 mouse model, Mol. Ther. Methods Clin. Dev., 31, 10.1016/j.omtm.2023.101144 · DOI
  133. Maino, 2021, Targeted genome editing in vivo corrects a Dmd duplication restoring wild-type dystrophin expression, EMBO Mol. Med., 13, 10.15252/emmm.202013228 · DOI
  134. Gushchina, 2021, Lack of Toxicity in Nonhuman Primates Receiving Clinically Relevant Doses of an AAV9.U7snRNA Vector Designed to Induce DMD Exon 2 Skipping, Hum. Gene Ther., 32, 882, 10.1089/hum.2020.286 · DOI
  135. Anzalone, 2019, Search-and-replace genome editing without double-strand breaks or donor DNA, Nature, 576, 149, 10.1038/s41586-019-1711-4 · DOI · Paper page
  136. Chemello, 2021, Precise correction of Duchenne muscular dystrophy exon deletion mutations by base and prime editing, Sci. Adv., 7, 10.1126/sciadv.abg4910 · DOI · Paper page
  137. Xu, 2021, Efficient precise in vivo base editing in adult dystrophic mice, Nat. Commun., 12, 3719, 10.1038/s41467-021-23996-y · DOI · Paper page
  138. Lin, 2024, Adenine base editing-mediated exon skipping restores dystrophin in humanized Duchenne mouse model, Nat. Commun., 15, 5927, 10.1038/s41467-024-50340-x · DOI
  139. Duchene, 2018, CRISPR-induced deletion with saCas9 restores dystrophin expression in dystrophic models in vitro and in vivo, Mol. Ther., 26, 2604, 10.1016/j.ymthe.2018.08.010 · DOI
  140. Choi, 2022, Precise genomic deletions using paired prime editing, Nat. Biotechnol., 40, 218, 10.1038/s41587-021-01025-z · DOI · Paper page
  141. Happi Mbakam, 2022, Prime editing permits the introduction of specific mutations in the gene responsible for Duchenne muscular dystrophy, Int. J. Mol. Sci., 23, 10.3390/ijms23116160 · DOI
  142. Pickar-Oliver, 2021, Full-length dystrophin restoration via targeted exon integration by AAV-CRISPR in a humanized mouse model of Duchenne muscular dystrophy, Mol. Ther., 29, 3243, 10.1016/j.ymthe.2021.09.003 · DOI
  143. Tasca, 2022, Large-scale genome editing based on high-capacity adenovectors and CRISPR-Cas9 nucleases rescues full-length dystrophin synthesis in DMD muscle cells, Nucleic Acids Res., 50, 7761, 10.1093/nar/gkac567 · DOI
  144. Stephenson, 2023, CRISPR-Cas9 homology-independent targeted integration of exons 1-19 restores full-length dystrophin in mice, Mol. Ther. Methods Clin. Dev., 30, 486, 10.1016/j.omtm.2023.08.009 · DOI
  145. Pandey, 2025, Efficient site-specific integration of large genes in mammalian cells via continuously evolved recombinases and prime editing, Nat. Biomed. Eng., 9, 22, 10.1038/s41551-024-01227-1 · DOI · Paper page
  146. Kenjo, 2021, Low immunogenicity of LNP allows repeated administrations of CRISPR-Cas9 mRNA into skeletal muscle in mice, Nat. Commun., 12, 7101, 10.1038/s41467-021-26714-w · DOI · Paper page
  147. Wei, 2020, Systemic nanoparticle delivery of CRISPR-Cas9 ribonucleoproteins for effective tissue specific genome editing, Nat. Commun., 11, 3232, 10.1038/s41467-020-17029-3 · DOI · Paper page
  148. Harrington, 2018, Programmed DNA destruction by miniature CRISPR-Cas14 enzymes, Science, 362, 839, 10.1126/science.aav4294 · DOI · Paper page
  149. Pausch, 2020, CRISPR-CasPhi from huge phages is a hypercompact genome editor, Science, 369, 333, 10.1126/science.abb1400 · DOI · Paper page
  150. Xu, 2021, Engineered miniature CRISPR-Cas system for mammalian genome regulation and editing, Mol. Cell, 81, 4333, 10.1016/j.molcel.2021.08.008 · DOI · Paper page
  151. Kong, 2023, Engineered CRISPR-OsCas12f1 and RhCas12f1 with robust activities and expanded target range for genome editing, Nat. Commun., 14, 2046, 10.1038/s41467-023-37829-7 · DOI
  152. Monteys, 2021, Regulated control of gene therapies by drug-induced splicing, Nature, 596, 291, 10.1038/s41586-021-03770-2 · DOI
  153. Arnett, 2014, Adeno-associated viral vectors do not efficiently target muscle satellite cells, Mol. Ther. Methods Clin. Dev., 1, 10.1038/mtm.2014.38 · DOI · Paper page
  154. Hauschka, 2024, Targeting muscle stem cells for permanent correction of dystrophin expression in Duchenne muscular dystrophy, Mol. Ther., 32, 550

Cited by

See all 40

Metadata

Authors
Bengtsson, N. E., Tasfaout, H., & Chamberlain, J. S.
Venue
Molecular Therapy
Publisher
Elsevier BV
Published
2025-05
Volume
33
Issue
5
Pages
2035-2051
ISSN
1525-0016
Cited by
40
References
46
Language
en
Licence
Funders
  • US Department of Defense (MD220097)
  • Muscular Dystrophy Association
  • Philippe Foundation
  • National Institute of Arthritis and Musculoskeletal and Skin Diseases (P50AR065139, R01AR040864)
  • National Institutes of Health
  • Association Française contre les Myopathies
  • AFM-Téléthon
  • Defeat Duchenne Canada
  • Fondation Bettencourt Schueller

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The road toward AAV-mediated gene therapy of Duchenne muscular dystrophy. https://app.cochat.ai/papers/10.1016/j.ymthe.2025.03.065
The paper
Bengtsson, N. E., Tasfaout, H., & Chamberlain, J. S. (2025). The road toward AAV-mediated gene therapy of Duchenne muscular dystrophy. Molecular Therapy. https://doi.org/10.1016/j.ymthe.2025.03.065

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.